JAZZ has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
JAZZ has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-19), Jazz Pharmaceuticals's current share price is $109.855. Jazz Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 was $4.51. Jazz Pharmaceuticals's Shiller PE Ratio for today is 24.36.
The historical rank and industry rank for Jazz Pharmaceuticals's Shiller PE Ratio or its related term are showing as below:
During the past years, Jazz Pharmaceuticals's highest Shiller PE Ratio was 3774.25. The lowest was 19.46. And the median was 32.05.
JAZZ's Shiller PE Ratio is ranked better thanE10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Jazz Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was $1.420. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $4.51 for the trailing ten years ended in Dec. 2023.
The historical data trend for Jazz Pharmaceuticals's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Jazz Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Jazz Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Jazz Pharmaceuticals's Shiller PE Ratio falls into.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
Jazz Pharmaceuticals's Shiller PE Ratio for today is calculated as
Shiller PE Ratio | = | Share Price | / | E10 |
= | 109.855 | / | 4.51 | |
= | 24.36 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Jazz Pharmaceuticals's E10 for the quarter that ended in Dec. 2023 is calculated as:
For example, Jazz Pharmaceuticals's adjusted earnings per share data for the three months ended in Dec. 2023 was:
Adj_EPS | = | Earnings per Share (Diluted) | / | CPI of Dec. 2023 (Change) | * | Current CPI (Dec. 2023) |
= | 1.42 | / | 120.1096 | * | 120.1096 | |
= | 1.420 |
Current CPI (Dec. 2023) = 120.1096.
Jazz Pharmaceuticals Quarterly Data
Earnings per Share (Diluted) | CPI | Adj_EPS | |
201403 | -1.580 | 100.573 | -1.887 |
201406 | 0.700 | 100.773 | 0.834 |
201409 | 0.410 | 100.474 | 0.490 |
201412 | 1.300 | 99.576 | 1.568 |
201503 | 1.120 | 99.975 | 1.346 |
201506 | 1.400 | 100.573 | 1.672 |
201509 | 1.390 | 100.274 | 1.665 |
201512 | 1.320 | 99.676 | 1.591 |
201603 | 1.210 | 99.676 | 1.458 |
201606 | 1.850 | 101.072 | 2.198 |
201609 | 1.450 | 100.274 | 1.737 |
201612 | 1.910 | 99.676 | 2.302 |
201703 | 1.410 | 100.374 | 1.687 |
201706 | 1.720 | 100.673 | 2.052 |
201709 | 1.030 | 100.474 | 1.231 |
201712 | 3.790 | 100.075 | 4.549 |
201803 | 0.750 | 100.573 | 0.896 |
201806 | 1.500 | 101.072 | 1.783 |
201809 | 2.410 | 101.371 | 2.856 |
201812 | 2.640 | 100.773 | 3.147 |
201903 | 1.470 | 101.670 | 1.737 |
201906 | 4.560 | 102.168 | 5.361 |
201909 | 1.780 | 102.268 | 2.091 |
201912 | 1.290 | 102.068 | 1.518 |
202003 | -2.820 | 102.367 | -3.309 |
202006 | 2.060 | 101.769 | 2.431 |
202009 | 2.640 | 101.072 | 3.137 |
202012 | 2.330 | 101.072 | 2.769 |
202103 | 2.090 | 102.367 | 2.452 |
202106 | -6.110 | 103.364 | -7.100 |
202109 | -0.860 | 104.859 | -0.985 |
202112 | -0.570 | 106.653 | -0.642 |
202203 | 0.030 | 109.245 | 0.033 |
202206 | 0.550 | 112.734 | 0.586 |
202209 | -0.310 | 113.431 | -0.328 |
202212 | -3.820 | 115.425 | -3.975 |
202303 | 1.040 | 117.618 | 1.062 |
202306 | 1.520 | 119.611 | 1.526 |
202309 | 2.140 | 120.708 | 2.129 |
202312 | 1.420 | 120.110 | 1.420 |
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Thank you for viewing the detailed overview of Jazz Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Jennifer E. Cook | director | C/O DENALI THERAPEUTICS INC., 151 OYSTER POINT BLVD., 2ND FLOOR, SOUTH SAN FRANCISCO CA 94080 |
Mark Douglas Smith | director | C/O TELADOC HEALTH, INC., 2 MANHATTANVILLE ROAD, SUITE 203, PURCHASE NY 10577 |
Neena M Patil | officer: SVP, General Counsel | JAZZ PHARMACEUTICALS, 3170 PORTER DRIVE, PALO ALTO CA 94304 |
Patricia Carr | officer: VP, Finance& PAO | JAZZ PHARMACEUTICALS, 3170 PORTER DRIVE, PALO ALTO CA 94304 |
Heather Ann Mcsharry | director | C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 |
Patrick G Enright | director, 10 percent owner | CO LONGITUDE CAPITAL PARTNERS LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025 |
Norbert G Riedel | director | BAXTER INTERNATIONAL INC, ONE BAXTER PKWY DF2-1W, DEERFIELD IL 60015 |
Catherine A. Sohn | director | C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 |
Rick E Winningham | director | 901 GATEWAY BOULEVARD, SOUTH SAN FRANCISCO CA 94080 |
Peter Gray | director | C/O JAZZ PHARMACEUTICALS PLC, 5TH FL, WATERLOO EXCHANGE, WATERLOO RD, DUBLIN L2 4 L2 |
Anne Oriordan | director | HOUSE 120, TAI HANG HAU VILLAGE, LOBSTER BAY, CLEARWATER BAY K3 HK |
Kenneth W O'keefe | director | C/O BEECKEN PETTY O'KEEFE & COMPANY, 131 S. DEARBORN STREET, SUITE 2800, CHICAGO IL 60603 |
Mary Elizabeth Henderson | officer: SVP, Technical Operations | 3170 PORTER DRIVE, PALO ALTO CA 94304 |
Renee D Gala | officer: EVP & CFO | 901 GATEWAY BLVD, SOUTH SAN FRANCISCO CA 94080 |
Kim Sablich | officer: EVP & GM, North America | C/O MYOVANT SCIENCES INC., 2000 SIERRA POINT PARKWAY, BRISBANE CA 94005 |
From GuruFocus
By PRNewswire • 09-11-2023
By PRNewswire PRNewswire • 05-25-2023
By PRNewswire • 09-21-2023
By ACCESSWIRE • 11-29-2023
By PRNewswire • 10-18-2023
By PRNewswire • 10-25-2023
By PRNewswire • 10-16-2023
By ACCESSWIRE • 12-08-2023
By GuruFocus Research GuruFocus Editor • 05-20-2023